PI4K2B Antibody

What is PI4K2B and why is it important in cellular research?

PI4K2B (Phosphatidylinositol 4-kinase type 2-beta) is a lipid kinase that phosphorylates phosphatidylinositol to generate phosphatidylinositol 4-phosphate (PIP), an immediate precursor of several important signaling and scaffolding molecules. PI4K2B is primarily cytosolic but gets recruited to membranes where it stimulates phosphatidylinositol 4,5-bisphosphate synthesis . The enzyme plays crucial roles in:

• Regulation of vesicular trafficking

• Trans-Golgi network (TGN) pools of PI(4)P maintenance

• Post-TGN membrane traffic

• Production of inositol 1,4,5-trisphosphate (InsP3) in stimulated cells

Research significance extends to cancer biology, as PI4K2B has been shown to negatively regulate invadopodia formation, suggesting its potential role as a suppressor of cancer invasion .

When validating PI4K2B antibodies, the following positive controls have been recommended:

• For Western blotting: Mouse brain lysate, Saos 2 cell lysate, and HepG2 cell lysate

• For IHC/IF: Human liver tissue and HepG2 cells show consistent positivity

• For recombinant expression validation: E. coli-derived human PI4K2B recombinant protein (Position: M1-K475)

The expected molecular weight for PI4K2B is approximately 50-54 kDa on Western blots, though the calculated molecular weight is 55 kDa .

How do different fixation methods affect PI4K2B antibody performance in immunohistochemistry?

Optimization of fixation protocols significantly impacts PI4K2B detection in tissues:

For paraffin-embedded tissues:

• Recommended antigen retrieval: TE buffer pH 9.0 provides optimal epitope exposure

• Alternative method: Citrate buffer pH 6.0 may be used but may yield lower signal intensity

For immunofluorescence:

• Paraformaldehyde fixation (4%) for 15-20 minutes at room temperature preserves antigenicity

• Methanol fixation may better preserve some epitopes depending on the specific antibody clone

Regardless of fixation method, blocking with appropriate protein blockers (5% BSA or 10% normal serum) is crucial to minimize background staining.

What are the critical considerations for detecting PI4K2B in subcellular localization studies?

PI4K2B exhibits dynamic subcellular localization that requires careful experimental design:

• Baseline localization: Primarily cytosolic with recruitment to:

  • Golgi apparatus membrane

  • Endoplasmic reticulum membrane

  • Cell membrane

  • Early endosome membrane

• Stimulation-dependent translocation: Association with membranes of the Golgi, endoplasmic reticulum, and plasma membrane is stimulated by active Rac1

• Co-localization markers needed:

  • Golgi markers (GM130, TGN46)

  • Endosomal markers (Rab5, Rab7, Rab8)

  • Plasma membrane markers (Na⁺/K⁺ ATPase)

• Imaging recommendations:

  • Super-resolution microscopy is preferred for precise co-localization studies

  • Z-stack imaging to fully capture membrane association dynamics

  • Live-cell imaging for translocation kinetics studies

How should experimental conditions be optimized for Western blotting of PI4K2B?

Successful Western blot detection of PI4K2B requires optimization of several parameters:

• Sample preparation:

  • Complete cell lysis buffers containing detergents (e.g., 1% Triton X-100)

  • Inclusion of phosphatase inhibitors to maintain phosphorylation status

  • Brief sonication may improve extraction from membrane fractions

• Gel percentage and transfer recommendations:

  • 8-10% SDS-PAGE gels for optimal separation around 50-54 kDa

  • Semi-dry transfer: 15V for 30 minutes or wet transfer at 100V for 60 minutes

• Blocking and antibody incubation:

  • 5% non-fat milk or 3-5% BSA in TBST for blocking (1 hour at room temperature)

  • Primary antibody incubation at 1:500-1:2400 dilution overnight at 4°C

  • Secondary antibody incubation at 1:5000-1:10000 for 1 hour at room temperature

• Signal development optimization:

  • Enhanced chemiluminescence (ECL) detection is sufficient for most applications

  • Exposure times ranging from 30 seconds to 5 minutes depending on expression levels

How can PI4K2B antibodies be utilized in cancer research to study its role in tumor invasiveness?

Emerging research has identified PI4K2B as a negative regulator of invadopodia formation and tumor cell invasion . For researchers studying this role:

• Experimental approaches:

  • siRNA knockdown studies: PI4KIIβ depletion in minimally invasive cell lines (HeLa, MCF-7) confers an aggressive invasive phenotype

  • Immunofluorescence co-localization: Track PI4K2B with MT1-MMP, a key factor in invasive structures

  • FITC-gelatin degradation assays: Quantitative measurement of matrix degradation capacity

• Data interpretation framework:

  • PI4KIIβ depletion causes increased MT1-MMP trafficking to invasive structures at the plasma membrane

  • Reduced colocalization of MT1-MMP with endosomal markers (Rab5, Rab7)

  • Increased localization with exocytic Rab8

• Clinical relevance assessment:

  • Loss of PI4K2B allele and underexpression of PI4KIIβ mRNA are associated with human cancers

  • Antibody staining of patient samples can validate this association in clinical specimens

What are the methodological approaches for studying PI4K2B's role in T-cell mediated immune responses?

PI4K2B has been identified as an HLA class II-restricted minor histocompatibility antigen (mHag) relevant to allogeneic stem cell transplantation . Researchers can:

• Experimental design for T-cell response studies:

  • Generate LB-PI4K2B-1S-specific CD4+ T cell lines from patients treated with donor lymphocyte infusions

  • Assess T-cell recognition of CD34+ chronic myeloid leukemia (CML) cells

  • Measure IFN-γ production in response to PI4K2B-derived epitopes

• Differential expression analysis:

  • Compare HLA-DQ expression between hematopoietic and non-hematopoietic cells

  • Assess IFN-γ-mediated upregulation of HLA-DQ on normal cells

• Functional assays:

  • Cytotoxicity assays measuring lysis of leukemic cells by PI4K2B-specific T cells

  • Helper function assessment for stimulating CD8+ T cell immunity

This research area highlights PI4K2B's potential role in graft versus leukemia (GvL) reactivity without graft versus host disease (GvHD) .

How can phosphorylation-specific PI4K2B antibodies be used to study kinase regulation?

While standard PI4K2B antibodies detect total protein levels, phosphorylation-specific antibodies enable more nuanced studies of regulation:

• Experimental setup for activation studies:

  • Stimulate cells with growth factors or other agonists to induce kinase activation

  • Use phosphorylation-specific antibodies to detect active vs. inactive forms

  • Employ phosphatase inhibitors during sample preparation to preserve phosphorylation status

• Quantitative analysis approaches:

  • Phospho/total PI4K2B ratio calculation for activation state assessment

  • Time-course experiments to track activation kinetics

  • Inhibitor dose-response studies to establish regulatory pathways

• Subcellular fractionation strategy:

  • Separate cytosolic and membrane fractions to track translocation

  • Correlate phosphorylation status with membrane recruitment

  • Assess co-immunoprecipitation with binding partners in different fractions

How should researchers address non-specific binding issues with PI4K2B antibodies?

Non-specific binding can compromise experimental results. Systematic troubleshooting includes:

• Validation strategies:

  • Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specificity

  • Knockout/knockdown controls: Use CRISPR/siRNA-treated samples as negative controls

  • Multiple antibody validation: Confirm results with antibodies targeting different epitopes

• Protocol optimization:

  • Increase blocking time/concentration (5% BSA for 2 hours)

  • Optimize antibody dilution through titration experiments

  • Add 0.1-0.3% Triton X-100 to antibody diluent to reduce hydrophobic interactions

  • Extend washing steps (5 x 5 minutes with gentle agitation)

• Application-specific adjustments:

  • For WB: Add 0.05% SDS to primary antibody solution to reduce non-specific binding

  • For IHC/IF: Pre-adsorb antibody with acetone powder from relevant tissues

  • For IP: Use protein A/G beads with lower binding capacity for IgG

What are the best practices for quantifying PI4K2B expression across different experimental systems?

Accurate quantification requires standardized approaches:

• Western blot densitometry:

  • Use housekeeping proteins appropriate for your experimental conditions (β-actin, GAPDH)

  • Apply rolling disk background subtraction before measurement

  • Ensure signals fall within linear dynamic range of detection

• Immunofluorescence quantification:

  • Standardize acquisition parameters (exposure time, gain, offset)

  • Set intensity thresholds based on negative controls

  • Measure integrated density rather than mean intensity when possible

  • Normalize to cell area or nuclear staining

• Flow cytometry analysis:

  • Use median fluorescence intensity rather than mean

  • Include isotype controls and FMO (fluorescence minus one) controls

  • Apply compensation to correct for spectral overlap

• qPCR normalization for protein-mRNA correlation:

  • Use multiple reference genes validated for your experimental system

  • Apply geometric averaging of reference genes for normalization

How can researchers ensure reproducibility when working with different lots of PI4K2B antibodies?

Lot-to-lot variation is a significant challenge. Best practices include:

• Initial lot validation:

  • Test new antibody lots alongside current lot

  • Document key performance metrics (signal intensity, background, specificity)

  • Create standard operating procedures (SOPs) with detailed validation criteria

• Internal standardization:

  • Maintain frozen aliquots of standard positive controls

  • Create a standard curve with recombinant PI4K2B protein

  • Normalize results to these standards across experiments

• Data normalization approaches:

  • Use relative quantification rather than absolute values

  • Apply statistical methods that account for batch effects

  • Include technical replicates spanning different antibody lots

• Comprehensive documentation:

  • Record antibody catalog numbers, lot numbers, and validation data

  • Document detailed experimental conditions to facilitate troubleshooting

  • Maintain a laboratory database of antibody performance metrics

How can PI4K2B antibodies be integrated with proteomics approaches to identify novel binding partners?

Combining immunoprecipitation with mass spectrometry enables comprehensive interactome mapping:

• Optimized IP-MS workflow:

  • Cross-linking prior to lysis can capture transient interactions

  • Use mild detergents (0.3% CHAPS) to preserve protein-protein interactions

  • Perform parallel IP with isotype control antibodies to identify non-specific binders

  • Include RNase/DNase treatment to eliminate nucleic acid-mediated interactions

• Data analysis strategies:

  • Apply SAINT (Significance Analysis of INTeractome) algorithm for statistical filtering

  • Prioritize proteins enriched in PI4K2B IP vs. controls by >5-fold

  • Validate top hits through reciprocal co-IP and co-localization studies

• Functional classification:

  • Group interacting proteins by cellular pathway and compartment

  • Perform Gene Ontology enrichment analysis to identify overrepresented functions

  • Construct protein-protein interaction networks using public databases

What approaches can resolve contradictory findings regarding PI4K2B subcellular localization?

Discrepancies in reported localization patterns can be addressed through:

• Technical resolution enhancements:

  • Super-resolution microscopy techniques (STED, PALM, STORM) to resolve structures below diffraction limit

  • Correlative light and electron microscopy (CLEM) to combine molecular specificity with ultrastructural detail

  • Live-cell imaging with photo-convertible tags to track dynamic relocalization

• Condition-dependent localization analysis:

  • Systematically test effects of cell confluence, cell cycle stage, and activation state

  • Examine localization across multiple cell types derived from different tissues

  • Compare endogenous vs. overexpressed protein localization patterns

• Epitope accessibility considerations:

  • Test multiple antibodies targeting different epitopes of PI4K2B

  • Apply different fixation and permeabilization methods that may expose different epitopes

  • Use genetic approaches (GFP-tagged PI4K2B) to complement antibody-based detection

How can PI4K2B antibodies contribute to understanding phosphoinositide dynamics in neurodegenerative diseases?

Emerging evidence links phosphoinositide metabolism to neurodegeneration:

• Tissue analysis methodology:

  • Optimize antigen retrieval for PI4K2B detection in brain tissue

  • Use dual immunofluorescence to correlate PI4K2B with disease markers

  • Analyze PI4K2B expression in different neuronal and glial populations

• Disease model applications:

  • Compare PI4K2B expression and localization across Alzheimer's, Parkinson's, and other neurodegenerative disease models

  • Assess correlation between PI4K2B levels and markers of cellular stress or protein aggregation

  • Examine PI4K2B redistribution during disease progression

• Therapeutic targeting assessment:

  • Use PI4K2B antibodies to evaluate effects of prospective drugs on enzyme expression and localization

  • Monitor phosphoinositide levels in response to treatments

  • Correlate PI4K2B activity with disease biomarkers

This emerging field represents an important frontier where PI4K2B antibodies can facilitate new discoveries about lipid signaling in neuronal health and disease.